Last $21.52 USD
Change Today +0.33 / 1.56%
Volume 135.5K
QDEL On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$21.10
Previous Close
$21.19
Day High
$21.64
Day Low
$20.94
52 Week High
01/15/14 - $32.24
52 Week Low
04/24/14 - $19.21
Market Cap
736.4M
Average Volume 10 Days
245.1K
EPS TTM
$-0.16
Shares Outstanding
34.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia RSV and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

572 Employees
Last Reported Date: 02/27/14
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $509.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $313.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $307.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Business Development...
Total Annual Compensation: $329.0K
Compensation as of Fiscal Year 2013.

quidel corp (QDEL) Key Developments

Quidel Corp. Receives FDA Clearance for Molecular PCR Assay for the Detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus

Quidel Corp. announced that it has received clearance, via the De Novo Request process, from the United States Food and Drug Administration (FDA) to market its Lyra(TM) Direct HSV 1+2/VZV multiplex real-time PCR assay. This new molecular test detects and differentiates herpes simplex viruses 1 and 2 (HSV 1+2) and varicella-zoster virus (VZV) nucleic acids isolated and purified from swab specimens taken from cutaneous (skin) or mucocutaneous (e.g., mouth, lips, or genitals) lesions on symptomatic patients. Quidel's latest assay for HSV 1+2/VZV is part of its exciting new Lyra brand of ready-to-use, molecular PCR reagent kits specifically designed to be compatible with a laboratory's existing thermocycler. The Lyra reagent kits provide attractive features that include a short time to result, ready-to-use master mix, and refrigerated, non-frozen storage of key reagents, as well as other benefits. Lyra Direct HSV1+2/VZV Assay distinguishes between three pathogenic viruses: HSV 1, the virus responsible for most cold sores and some genital herpes transmissions; HSV 2, the virus primarily responsible for most genital herpes and some cold sores; and VZV, the virus responsible for chicken-pox in children and shingles among adults. The Centers for Disease Control and Prevention (CDC) estimates that there are almost 800,000 new cases of herpes in the United States each year, and about 1 in 6 Americans aged 14 to 49 have a genital HSV 2 infection. The Lyra Direct HSV 1+2/VZV Assay kit includes an extraction-free, three-step sample preparation process that does not require time-consuming automated extraction. This fast and easy direct-to-amplification procedure allows the assay to generate a result in approximately 50 minutes.

Quidel Corp. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM

Quidel Corp. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director, Randy Steward, chief financial officer, Ruben Argueta, Director of IR.

Quidel Corporation Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

Quidel Corporation reported unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of $46.7 million compared to total revenues of $62.0 million in the first quarter of 2013. The decrease in revenue was due to lower sales of infectious disease products in the first quarter of 2014, the result of a weak respiratory disease season. Net loss was $1.5 million, or $0.04 per basic and diluted share compared to net income of $12.4 million, or $0.36 per diluted share, for the first quarter of 2013. Operating loss was $2,187,000 compared to operating income of $17,189,000 last year. Loss before taxes was $2,376,000 compared to income before taxes $16,991,000 last year. On a non-GAAP basis, excluding amortization of intangibles, stock compensation expense and certain non-recurring items, net income for the first quarter of 2014 was $2.9 million, or $0.08 per diluted share, compared to $17.0 million, or $0.49 per diluted share, for the same period in 2013. Tax rate for the quarter was 36% as compared to 27% last year. In the first quarter, the company generated cash from operating activities of $22.2 million and incurred $4 million in capital expenditures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $21.52 USD +0.33

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $75.94 USD -0.46
Ion Beam Applications €12.18 EUR +0.17
Luminex Corp $16.81 USD +0.62
Meridian Bioscience Inc $20.58 USD +0.21
OraSure Technologies Inc $8.29 USD -0.10
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 3.2x
Price/Cash Flow 341.1x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.